|||Page||
|---|---|---|---|
|Reference and Administrative<br>Details||||
|Report of the Trustees|2|to|4|
|Independent<br>Examiner's<br>Report||||
|Statement<br>of Financial<br>Activities||||
|Balance Sheet|7|to|8|
|Notes to the Financial Statements|9|to|16|
|Detailed Statement<br>of Financial<br>Activities|17|to|18|





## 



## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 

## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 



## 



## 

|for the Ye|ar Ended||1 Janua<br>|2021||||||
|---|---|---|---|---|---|---|---|---|---|
|||||||||2021|2020|
|||||||Unrestricted|Restricted|Total|Total|
|||||||fund|funds|funds|funds|
||||||Notes|6|f|6|F|
|INCOME|AND ENDOWMENTS|||FROM||||||
|Donations|and legacies|||||4,521||4,521|122,389|
|Charitable|activities|||||||||
|Charitable|activities||||||227,819|227,819|226,642|
|Investment|income||||3|4,341||4,341|4,816|
|Total||||||8,862|227,819|236,681|353,847|
|EXPENDITURE ON||||||||||
|Charitable|activities|||||||||
|Charitable|activities|||||9,842|148,536|158,378|226,027|
|Net gains|on investments|||||17,267||17,267|20,486|
|NET INCOME||||||16,287|79,283|95,570|148,306|
|Transfers|between||funds||10|(42,782)|42,782|||
|Net movement<br>in funds||||||(26,495)|122,065|95,570|148,306|
|RECONCILIATION||OF FUNDS||||||||
|Total funds brought|||forward|||1,082,281|395,626|1,477,907|1,329,601|
|TOTAL FUNDS CARRIED FORWARD||||||1,055,786|517,691|1,573,477|1,477,907|





|Balance Sheet<br>3~1J<br>2021||||||
|---|---|---|---|---|---|
|||||2021|2020|
|||Unrestricted|Restricted|Total|Total|
|||fund|funds|funds|funds|
||Notes|5|6|F|6|
|FIXEDASSETS||||||
|Investments|7|234,123||234,123|212,770|
|CURRENT ASSETS||||||
|Debtors|8|421,607|241,304|662,911|504,419|
|Cash at bank||402,484|421,954|824,438|837,727|
|||824,091|663,258|1,487,349|1,342,146|
|CREDITORS||||||
|Amounts<br>falling due within one year|9|(2,428)|(145,567)|(147,995)|(77,009)|
|NET CURRENT ASSETS||821,663|517,691|1,339,354|1,265,137|
|TOTAL ASSETS LESSCURRENT||||||
|LIABILITIES||1,055,786|517,691|1,573,477|1,477,907|
|NET ASSETS||1,055,786|517,691|1,573,477|1,477,907|
|FUNDS|10|||||
|Unrestricted<br>funds||||1,055,786|1,082,281|
|Restricted<br>funds||||517,691|395,626|
|TOTAL FUNDS||||1,573,477|1,477,907|





## 



## 

## 

## 

## 

## 

## 

## 

## 

## 



## 

## 

## 

|INVESTMENT|INVESTMENT|INCOME||||
|---|---|---|---|---|---|
||||2021||2020|
||||E||6|
|Dividend|income||4,329||4,791|
|Deposit|account|interest||12|25|
||||4,|341|4,816|



## 

## 

## 

|No employee<br>received<br>remuneration<br>amounting<br>to more than|No employee<br>received<br>remuneration<br>amounting<br>to more than|No employee<br>received<br>remuneration<br>amounting<br>to more than|860,000 in eit|her year.||
|---|---|---|---|---|---|
|COMPARATIVES<br>FOR THE STATEMENT OF FINANCIAL|||ACTIVITIES|||
||||Unrestricted|Restricted|Total|
||||fund|funds|funds|
||||8|F|8|
|INCOME AND ENDOWMENTS||FROM||||
|Donations|and legacies||122,389||122,389|
|Charitable|activities|||||
|Charitable|activities|||226,642|226,642|
|Investment|income||4,816||4,816|
|Total|||127,205|226,642|353,847|
|EXPENDITURE<br>ON||||||
|Charitable|activities|||||
|Charitable|activities||15,578|210,449|226,027|
|Net gains|on investments||20,486||20,486|
|NET INCOME|||132,113|16,193|148,306|





## 

|for t|he Year Ended 31 Janua<br>2021|he Year Ended 31 Janua<br>2021|he Year Ended 31 Janua<br>2021|he Year Ended 31 Janua<br>2021|he Year Ended 31 Janua<br>2021|he Year Ended 31 Janua<br>2021|he Year Ended 31 Janua<br>2021|he Year Ended 31 Janua<br>2021|he Year Ended 31 Janua<br>2021|he Year Ended 31 Janua<br>2021|he Year Ended 31 Janua<br>2021|||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
||COMPARATIVES<br>FOR THE STATEMENT OF FINANCIAL ACTIVITIES|||||||||||-continued||
|||||||||||Unrestricted||Restricted|Total|
||||||||||||fund|funds|funds|
||||||||||||E|F|6|
||Transfers<br>between|funds|||||||||(41,293)|41,293||
||Net movement<br>in funds||||||||||90,820|57,486|148,306|
||RECONCILIATION<br>OF FUNDS|||||||||||||
||Total funds<br>brought|forward|||||||||991,461|338,140|1,329,601|
||TOTAL FUNDS CARRIED FORWARD|||||||||1,082,281||395,626|1,477,907|
|7.|FIXEDASSET INVESTMENTS|||||||||||||
||||||||Shares||in|||||
||||||||gl'oup||||Listed|Other||
|||||||undertakings<br>F||||investments<br>F||investments<br>6|Totals<br>f|
||MARKET VALUE|||||||||||||
||At 1 February 2020<br>Additions||||||||||191,128<br>8,493|21,641|212,770<br>8,493|
||Disposals<br>Revaluations||||||||||(4,407)<br>18,565|(1,298)|(4,407)<br>17,267|
||At 31 January<br>2021|||||||||213,779||20,343|234,123|
||NET BOOK VALUE|||||||||||||
||At 31 January<br>2021|||||||||213,779||20,343|234,123|
||At 31 January<br>2020||||||||||191,128|21,641|212,770|
||There were no investment||assets||outside|the|UK.|||||||
||The company<br>owns|100%of the|||issued share||capital||of|ABCD (Diabetes||Care) Limited, a company||
||incorporated<br>and<br>registered|||in|England|and|Wales.|||The|aggregate|capital<br>and|reserves<br>of<br>t|
||company<br>at 31 January<br>to 31 January<br>2021 was||2021<br> 827,|were f25,149(2020: <br>325 (2020; fNil). The|||||8-2,176).The profit <br> loss of the company|||of the company<br>for the<br>ye<br>for the year to 31<br>Januar||
||2021 was<br>Nil (2020:|E2,326).||||||||||||
||DEBTORS: AMOUNTS||FALLING DUE WITHIN|||||ONE YEAR||||||
|||||||||||||2021|2020|
|||||||||||||f|E|
||Amounts<br>owed by group <br>VAT||undertakings|||||||||662,607<br>304|504,115<br>304|
|||||||||||||662,911|504,419|





|Year Ended 31 Janua<br>2|Year Ended 31 Janua<br>2|021|021||||
|---|---|---|---|---|---|---|
|CREDITORS: AMOUNTS||FALLING DUE WITHIN ONE||YEAR|||
||||||2021|2020|
|Amounts<br>owed to group undertakings<br>Accruals and deferred<br>income|||||145,567<br>2,428|74,582<br>2,427|
||||||147,995|77,009|
|MOVEMENT<br>IN FUNDS|||||||
|||||Net|Transfers||
|||||movement|between|At|
||||At 1/2/20|in funds|funds|31/1/21|
||||f||E|8|
|Unrestricted<br>funds|||||||
|General<br>fund|||1,082,281|16,287|(42,782)|1,055,786|
|Restricted funds|||||||
|National<br>Audit Programmes|||1,014|||1,014|
|National<br>Liragutide<br>& <br>Scheme|Exenatide||29,489|||29,489|
|Degludec<br>Nationwide<br>Canagliflozin<br>audit<br>Libre audit|Audit||19,465<br>63,032<br>69,236|(11,236)<br>53,728||19,465<br>51,796<br>122,964|
|Testosterone<br>audit|||79,664|(31,236)||48,428|
|Semaglutide<br>audit<br>Empagliflozin<br>audit<br>ABCD Research<br>fund|||131,665|99,106<br>3,764<br>(42,520)|42,520|230,771<br>3,764|
|Haemodialysis<br>project<br>COVID Diabetes<br>National||Audit|2,061|(2,323)<br>10,000|262|10,000|
||||395,626|79,283|42,782|517,691|
|TOTAL FUNDS|||1,477,907|95,570||1,573,477|
|Net movement<br>in funds,||included|in the above are as follows:||||
||||Incoming|Resources|Gains and|Movement|
||||resources<br>8|expended<br>8|losses<br>f|in funds<br>E|
|Unrestricted<br>funds|||||||
|General<br>fund|||8,862|(9,842)|17,267|16,287|
|Restricted<br>funds|||||||
|Canagliflozin<br>audit<br>Libre audit|||5,000<br>72,477|(16,236)<br>(18,749)||(11,236)<br>53,728|
|Testosterone<br>audit|||5,000|(36,236)||(31,236)|
|Semaglutide<br>audit<br>Empagliflozin<br>audit<br>ABCD Research<br>fund|||115,342<br>20,000|(16,236)<br>(16,236)<br>(42,520)||99,106<br>3,764<br>(42,520)|
|Haemodialysis<br>project<br>COVID Diabetes<br>National||Audit|10,000|(2,323)||(2,323)<br>10,000|
||||227,819|(148,536)||79,283|
|TOTAL FUNDS|||236,681|(158,378)|17,267|95,570|



## 

## 



## 

## 

|Comparatives<br>for mo|veme|nt<br>in fund|s||||||
|---|---|---|---|---|---|---|---|---|
||||||Net|Transfers|||
||||||movement|between||At|
|||||At 1/2/19|in funds|funds||31/1/20|
||||||E|F||E|
|Unrestricted<br>funds|||||||||
|General<br>fund||||991,461|132,113|(41,293)||1,082,281|
|Restricted<br>funds|||||||||
|National<br>Audit Programmes||||1,238|(224)|||1,014|
|NHS Priorities Scheme||||11,725|(48,081)|36,356|||
|National<br>Liragutide<br>&|Exenatide||||||||
|Scheme||||37,566|(8,077)|||29,489|
|Revise Research<br>Project||||5,186|(9,446)|4,260|||
|Degludec<br>Nationwide<br>Audit<br>Nationwide<br>Audit Therapies||Audit fund||27, 542|(8,077)<br>(195)||195|19,465|
|Canagliflozin<br>audit<br>Libre audit||||61,429<br>44,470|1,603<br>24,766|||63,032<br>69,236|
|Testosterone<br>audit||||67,742|11,922|||79,664|
|Semaglutide<br>audit||||81,242|50,423|||131,665|
|Empagliflozin<br>audit<br>Haemodialysis<br>project|||||(482)<br>2,061||482|2,061|
|||||338,140|16,193|41,293||395,626|
|TOTAL FUNDS|||1,329,601||148,306|||1,477,907|
|Comparative<br>net movement||in funds,|included|in the above|are as follows:||||
|||||Incoming|Resources|Gains and||Movement|
|||||resources|expended|losses||in funds|
|||||E|8|5||E|
|Unrestricted<br>funds|||||||||
|General<br>fund||||127,205|(15,578)|20,486||132,113|
|Restricted<br>funds|||||||||
|National<br>Audit Programmes|||||(224)|||(224)|
|NHS Priorities Scheme|||||(48,081)|||(48,081)|
|National<br>Liragutide<br>8|Exenatide||||||||
|Scheme|||||(8,077)|||(8,077)|
|Revise Research Project|||||(9,446)|||(9,446)|
|Degludec<br>Nationwide|Audit||||(8,077)|||(8,077)|
|Nationwide<br>Audit Therapies||Audit fund|||(195)|||(195)|
|Canagliflozin<br>audit<br>Libre audit||||20,000<br>80,642|(18,397)<br>(55,876)|||1,603<br>24,766|
|Testosterone<br>audit||||45,000|(33,078)|||11,922|
|Semaglutide<br>audit||||68,500|(18,077)|||50,423|
|Empagliflozin<br>audit<br>Haemodialysis<br>project||||10,000<br>2,500|(10,482)<br>(439)|||(482)<br>2,061|
|||||226,642|(210,449)|||16,193|
|TOTAL FUNDS||||353,847|(226,027)|20,486||148,306|





## 

## 

|A current year 12 mon|ths<br>|a|nd prior year|12 months<br>combi|ned<br>position<br>is|as follows:||
|---|---|---|---|---|---|---|---|
||||||Net|Transfers||
||||||movement|between|At|
|||||At 1/2/19|in funds|funds|31/1/21|
|||||f|f|5|6|
|Unrestricted<br>funds||||||||
|General<br>fund||||991,461|148,400|(84,075)|1,055,786|
|Restricted funds||||||||
|National<br>Audit Programmes||||1,238|(224)||1,014|
|NHS Priorities Scheme||||11,725|(48,081)|36,356||
|National<br>Liragutide<br>&|Exenatide|||||||
|Scheme||||37,566|(8,077)||29,489|
|Revise Research Project<br>Degludec<br>Nationwide<br>Audit<br>Nationwide<br>Audit Therapies<br>Canagliflozin<br>audit<br>Libre audit|||Audit fund|5,186<br>27, 542<br>61,429<br>44,470|(9,446)<br>(8,077)<br>(195)<br>(9,633)<br>78,494|4,260<br>195|19,465<br>51,796<br>122,964|
|Testosterone<br>audit||||67,742|(19,314)||48,428|
|Semaglutide<br>audit<br>Empagliflozin<br>audit||||81,242|149,529<br>3,282|482|230,771<br>3,764|
|ABCD Research<br>fund|||||(42,520)|42,520||
|Haemodialysis<br>project<br>COVID Diabetes<br>National||Audit|||(262)<br>10,000|262|10,000|
|||||338,140|95,476|84,075|517,691|
|TOTAL FUNDS||||1,329,601|243,876||1,573,477|





## 


## 

## 



|Detailed Statement<br>of Financial|Detailed Statement<br>of Financial|Detailed Statement<br>of Financial|Activities|||
|---|---|---|---|---|---|
|for the Year Ended 31 Janua|||2021|||
|||||2021|2020|
|||||6|F|
|INCOME AND ENDOWMENTS||||||
|Donations<br>and legacies||||||
|Donations||||4,521|122,389|
|Investment<br>Income||||||
|Dividend<br>income||||4,329|4,791|
|Deposit account interest||||12|25|
|||||4,341|4,816|
|Charitable<br>activities||||||
|Semaglutide<br>audit||||115,341|68,500|
|Libre audit||||72,478|80,642|
|Testosterone<br>audit||||5,000|45,000|
|Canagliflozin<br>audit||||5,000|20,000|
|Empagliflozin<br>audit||||20,000|10,000|
|Haemodialysis<br>project|||||2,500|
|COVID diabetes<br>national||audit||10,000||
|||||227,819|226,642|
|Total incoming<br>resources||||236,681|353,847|
|EXPENDITURE||||||
|Charitable<br>activities||||||
|National<br>Audit Programme|||||224|
|NHS Priorities Scheme|||||48,081|
|Canagliflozin<br>Audit Scheme||||16,236|18,397|
|Revise Research project<br>Libre audit||||18,749|9,446<br>55,876|
|Liraglutide<br>& Exenatide|Audit||||8,077|
|Testosterone<br>audit||||36,236|33,078|
|Semaglutide<br>audit||||16,236|18,077|
|Degludec<br>audit<br>Nationwide<br>new therapies||audit||2,323|8,077<br>195|
|Empagliflozin<br>audit||||16,236|10,482|
|ABCD Research<br>fund||||42,520||
|Haemodialysis<br>project|||||439|
|||||148,536|210,449|
|Support costs||||||
|Management<br>Accountancy<br>fees<br>Insurance||||3,953<br>1,959|3,643<br>1,599|
|Trustee costs||||58|8,716|
|Professional<br>fees||||1,150||
|Carried<br>forward||||7,120|13,958|





## 

|Detailed Statement|of|Financial|Activities|||
|---|---|---|---|---|---|
|for the Year Ended|31|Janua|2021|||
|||||2021|2020|
|||||F|E|
|Management||||||
|Brought forward||||7,120|13,958|
|Investment<br>manager||fees||2,650|1,548|
|Bank charges||||72|72|
|||||9,842|15,578|
|Total resources expended||||158,378|226,027|
|Net Income before|gains and||losses|78,303|127,820|
|Realised recognised||gains and losses||||
|Realised gains/(losses)||on fixed|asset|||
|investments||||17,267|20,486|
|Net Income||||95,570|148,306|